Last updated on February 2018

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

Brief description of study

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) [ADAS-Cog 13], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) [ADCS-ADL-MCI].

Clinical Study Identifier: NCT02477800

Contact Investigators or Research Sites near you

Start Over

John Scott

National Clinical Research Inc.-Richmond
Richmond, VA United States
  Connect »